- Poster Presentation Showcases Patient Motivation to Seek a New Procedure to Clear Common Benign Lesions

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the presentation of an ePoster at the American Academy of Dermatology (AAD) Virtual Annual Meeting taking place on April 23-25, 2021. Pulse Biosciences will showcase results of primary consumer research, conducted by medical technology marketing research firm (Collective Acumen Inc., Greenwich, CT), evaluating the unmet need and patient motivation for an elegant procedure to clear benign skin lesions.

“We see many aesthetic patients with visible skin lesions that have a substantial impact on their psychosocial health and quality of life. More than a nuisance, these skin lesions often become a burden affecting patients in terms of their physical appearance, self-confidence and other important aspects of life,” said Thomas Rohrer, MD, a leading dermatologic surgeon at the SkinCare Physicians Group of Chestnut Hill, Massachusetts. “This study of patient perceptions reminds us that patients have their own preferences and priorities regarding treatments that are important. In the case of patients with unwanted benign lesions, a majority report they are highly motivated to seek a solution that provides both clinical efficacy and improved aesthetic results.”

A diverse sample of 405 aesthetic patients in the U.S. who are likely to pay cash to improve their skin condition participated in the online survey. Participants with the target lesions were provided a procedure description modeling the potential CellFX profile and its unique cell-specific NPS mechanism, as well as before and after photos from controlled clinical studies of target lesions. Results indicated that on average 76% of aesthetic patients rated the value of a new procedure to clear lesions higher overall than other popular aesthetic procedures, such as botulinum toxin or fillers, that they have paid for in the past, and would prioritize clearing lesions over these other common available procedures.

“This consumer research was conducted to better understand unmet needs, particularly the benefit and economic value of clearing common lesions for these aesthetic patients,” said Darrin Uecker, CEO and President of Pulse Biosciences. “We were pleased that the findings validated a genuine patient desire for a long-lasting solution to clear lesions that produces a visible, clear difference that contributes to how they look and feel.”

Pulse Biosciences also announced the launch of its new CellFX.com website. Physicians and patients are invited to explore the online resource and learn more about the benefits of the CellFX procedure. Content-rich, the new site was designed with the user experience in mind and offers easy navigation and useful information, including expert remarks, clinical resources, infographics, video clips and before and after photo sets.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.

To stay informed about the CellFX System, please visit CellFX.com and sign up for updates.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences’ expectations regarding regulatory clearance and the timing of regulatory filings or approvals, NPS technology including the effectiveness of such technology, the CellFX System including the benefits of the CellFX System and commercialization and adoption of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Company’s market opportunity and commercialization plans, including the timing and results of the controlled launch in the US, the market for the treatment of certain lesions, the experience of using the CellFX System, future financial performance, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005425/en/